Researchers exploit rhythm of DNA replication to kill cancer cells

Researchers exploit rhythm of DNA replication to kill cancer cells
Credit: University of Copenhagen

Human cells divide and create new cells throughout life. In this process, a steady—even rhythmic—supply of DNA building blocks is needed to create new DNA. Now researchers from the University of Copenhagen are the first to show exactly how human cells regulate this process so it does not fail and cause illness. The researchers also show how they can manipulate the rhythm and suggest how this can be used in the future to kill cancer cells. The study is published in Science.

New DNA is generated in from tiny building blocks called nucleotides produced by an enzyme called RNR. Until now, we have not fully understood how exactly the RNR rhythm and the presence of right amount of nucleotides are aligned with the pace of DNA .

Now, researchers from the Faculty of Health and Medical Sciences at the University of Copenhagen have mapped the flow and regulation of nucleotides. The flow follows the same rhythm as replication of DNA does - and when it does not, the cells regulate the process to align the two.

"We can see that these processes follow the same periodic rhythm. We found a mechanism that instantly slows down DNA-replication when RNR, the nucleotide factory, gets out of that rhythm, but well before the nucleotide supply becomes critically low, says Jiri Lukas Professor and Executive Director at The Novo Nordisk Foundation Center for Protein Research.

Building blocks catching up

The research groups led by Professors Jiri Lukas and Chunaram Choudhary found that the cell reacts to even small changes in the flow of nucleotides. If the production falters, a chemical signal consisting of reactive oxygen species (ROS) spreads the message to slow down the DNA replication.

Their research paper; published today in the journal Science, reports that such communication between nucleotide supply and DNA replication speed is possible thanks to the fact that all sites in human genome that actively copy DNA contain a protein called PRDX2 that senses this chemical alert.

When this happens, the PRDX2 protein releases an accelerator called TIMELESS from the DNA, and this release slows down the pace with which cell cope their DNA. Slower DNA replications allows for the production of nucleotides to catch up and get back to the same rhythm with DNA synthesis. Because of this, there are almost always enough nucleotides to build the DNA, which is turn is critically important for the copying the healthy genomes without mistakes.

High speed kills cancer

This finding sheds light on several illnesses, but is especially important in relation to . The researchers show that they can deactivate the chemical signal that alerts the cells to problems with production. Under such conditions, cells cannot slow down the replication process, and the researchers propose that this would impede proliferation of cancer cells because they are particularly vulnerable to a high replication speed.

"We found that cancer copy their DNA rather slow, because they have abnormal genomes and replicating DNA has to overcome many obstacles. When we remove their ability to copy their genomes slowly, the die because they cannot cope with too many bumps on their DNA templates," says Kumar Somyajit, Post.Doc and first author of the study.

More information: Kumar Somyajit et al, Redox-sensitive alteration of replisome architecture safeguards genome integrity, Science (2017). DOI: 10.1126/science.aao3172

Journal information: Science

Citation: Researchers exploit rhythm of DNA replication to kill cancer cells (2017, November 10) retrieved 28 March 2024 from https://phys.org/news/2017-11-exploit-rhythm-dna-replication-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Findings pave way for three-drug combination treatment for childhood leukemia

492 shares

Feedback to editors